Opportunity Overview
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient Dasatinib (excluding strength 100 mg in standard sizes N2 and N3, ATC L01EA02, valid from 01.11.24 to 31.10.26).
This is one of 1,481 active Germany Pharmaceuticals opportunities most of your competitors will never see.
Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.
Start FreeSolicitation Details
| Issuing agency | Health |
|---|---|
| Country | Germany |
| Category | Pharmaceuticals |
| Published | September 17, 2024 |
| Response due | August 29, 2026 |
| Status | Active - open for responses |
| Official source | View original notice |
Related Opportunities in Germany
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Metronidazol
See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.
Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.
Start Free Trial — No Card RequiredFree 14-day trial · no card required
See who is already competing here →